Eisai US announced a recent advancement to address unmet needs for early Alzheimer's disease.
Published
Signal category
Research & Knowledge
Quote
“We are proud to share a recent advancement to help address the unmet needs of the AD community.”
— Eisai US team
Company
Eisai US
Breaking through in the therapeutic areas of oncology and neurology. View our community guidelines: https://bit.ly/3dkY
- Industry
- Pharmaceutical Manufacturing
- Location
- Nutley, US
- Company size
- 2,733 employees
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
Founded 1995